← Research index  ·  Disorder page  ·  Source YAML

Cross-provider research synthesis

Allergic Cutaneous Vasculitis

MONDO:0001290 Curated 2026-07-04T00:00:00Z 9 harmonized findings
falcon · 23 citations openscientist · 29 citations
Concordant asserts the finding Partial supports a weaker/qualified form Contradictory conflicts with it Silent does not address it

Harmonized findings

Allergic cutaneous vasculitis (cutaneous small-vessel / leukocytoclastic vasculitis) is an acquired, immune-complex-mediated (Gell-Coombs type III hypersensitivity) small-vessel vasculitis targeting the superficial dermal postcapillary venules.

UNANIMOUS INTEGRATED
pathophysiology
ProviderStanceScoreEvidence
falcon CONCORDANT 90% A widely used mechanistic chain for immune-complex (type III) cutaneous vasculitis is:
Falcon frames the disorder as an immune-complex (type III) cutaneous vasculitis and lays out the trigger-to-lesion mechanistic chain.
DOI:10.20431/2456-0022.0807003, DOI:10.3389/fmed.2023.1103065
openscientist CONCORDANT 95% is a Type III hypersensitivity immune complex-mediated small vessel vasculitis that predominantly affects postcapillary venules in the dermis.
OpenScientist states the same type III immune-complex mechanism and adds the precise postcapillary-venule target in the dermis.
PMID:3159805

The pathogenic cascade proceeds from immune-complex deposition through classical-pathway complement activation (C3a/C5a) and neutrophil recruitment/degranulation to fibrinoid necrosis of the vessel wall, leukocytoclasia, and red-blood-cell extravasation.

UNANIMOUS INTEGRATED
pathophysiology
ProviderStanceScoreEvidence
falcon CONCORDANT 92% 4) **Classical complement cascade activation** (C3a/C5a generation) → 5) **mast cell degranulation and histamine release** → 6) **neutrophil recruitment and degranulation** → 7) **fibrinoid necrosis of vessel walls** and leukocytoclasia → 8) **RBC extravasation** causing non-blanching purpura.
Falcon gives the ordered complement/neutrophil cascade ending in fibrinoid necrosis and RBC extravasation, and additionally emphasizes an upstream mast-cell degranulation step.
DOI:10.20431/2456-0022.0807003
openscientist CONCORDANT 90% activating the complement sequence with elaboration of chemotactic factors for neutrophils. These cells release lysosomal enzymes resulting in vessel wall destruction
OpenScientist (quoting Sams) describes the same complement activation → neutrophil chemotaxis → lysosomal-enzyme-mediated vessel-wall destruction.
PMID:3159805

Palpable purpura on dependent areas (typically the lower extremities) is the cardinal clinical manifestation.

UNANIMOUS INTEGRATED
phenotype
ProviderStanceScoreEvidence
falcon CONCORDANT 90% producing **palpable purpura** and related purpuric/urticarial lesions, most often on dependent areas (lower legs)
Falcon names palpable purpura on dependent lower-leg areas as the core cutaneous phenotype.
DOI:10.1007/s40257-022-00736-6
openscientist CONCORDANT 92% Palpable purpura on the lower extremities is recognized as the most reliable hallmark
OpenScientist, citing the 2025 EADV consensus, calls lower-extremity palpable purpura the most reliable diagnostic hallmark.
PMID:41399325

Diagnosis rests on skin biopsy of a fresh (roughly 24-48 hour old) lesion showing the histopathologic triad of leukocytoclasia, fibrinoid necrosis, and RBC extravasation, supplemented by direct immunofluorescence.

UNANIMOUS INTEGRATED
diagnosis
ProviderStanceScoreEvidence
falcon CONCORDANT 88% biopsy ideally from a lesion **~24–48 hours** old / **1–2 days** old to optimize diagnostic yield
Falcon specifies the optimal biopsy timing window and (elsewhere) the leukocytoclasia/fibrinoid-necrosis histology plus recommended DIF.
DOI:10.1007/s40257-022-00736-6
openscientist CONCORDANT 90% Biopsies should be taken from fresh lesions (<48 hours old) and should include all layers of the skin through subcutis
OpenScientist calls biopsy the gold standard from fresh (<48 h) lesions and separately enumerates the same histopathologic triad, with DIF sensitivity ~75%.
PMID:18415063, PMID:39307568

Cutaneous vasculitis is roughly as common as systemic vasculitis, with a reported annual incidence of biopsy-proven disease on the order of 15-38 per million per year.

UNANIMOUS INTEGRATED
epidemiology
ProviderStanceScoreEvidence
falcon CONCORDANT 85% **Incidence:** **15–38 per million/year**
Falcon reports an incidence range of 15-38 per million per year for biopsy-proven cutaneous LCV.
DOI:10.1007/s11739-021-02688-x
openscientist CONCORDANT 90% The overall annual incidence of cutaneous vasculitis was 38.6/million (95% CI 30.6-48.1), and for CLA 15.4/million (95% CI 10.6-21.8)
OpenScientist gives concordant Norfolk-registry figures (38.6/million all cutaneous vasculitis; 15.4/million CLA), the endpoints of Falcon's range.
PMID:9598892

The disease is most often triggered by drugs and infections, but a large fraction (up to ~50%) of cases is idiopathic.

MAJORITY INTEGRATED
pathophysiology
ProviderStanceScoreEvidence
falcon PARTIAL 55% Often idiopathic, but common triggers include **medications** (especially **beta-lactams/other antibiotics**), **infections**
Falcon lists the same trigger categories (idiopathic, drugs, infections) qualitatively but does not quantify the fractions.
DOI:10.1007/s40257-022-00736-6, DOI:10.1007/s11739-021-02688-x
openscientist CONCORDANT 90% Drugs and preceding infections were identified as precipitating factors in 40% and 20% of cases, respectively
OpenScientist quantifies the etiology breakdown (drugs ~40%, infections ~20%, idiopathic up to 50%), which Falcon reports only qualitatively.
PMID:28328827, PMID:39072425

The prognosis is generally favorable and self-limited, but a substantial minority of patients develop a chronic or relapsing course.

UNANIMOUS INTEGRATED
prognosis
ProviderStanceScoreEvidence
falcon CONCORDANT 85% ~**90%** resolve spontaneously within weeks to months
Falcon reports ~90% spontaneous resolution within weeks to months and ~10% developing a chronic/relapsing course.
DOI:10.1007/s40257-022-00736-6
openscientist CONCORDANT 80% 18-25% of patients experience relapse.
OpenScientist agrees the disease is benign/self-limited but frames the relapsing minority as an 18-25% relapse rate, a higher figure than Falcon's ~10% chronic/relapsing estimate (quantitative difference, not a conflict).
PMID:28328827, PMID:27428231

Management centers on removal of the trigger plus supportive care, escalating to colchicine (first-line) and dapsone (second-line) for chronic/relapsing disease, with corticosteroids and immunosuppressants reserved for severe or refractory cases.

UNANIMOUS INTEGRATED
treatment
ProviderStanceScoreEvidence
falcon CONCORDANT 90% supportive measures (rest, elevation, compression), topical steroids/NSAIDs if appropriate, plus **removal of the trigger** (stop offending drug; treat infection).
Falcon gives the same stepwise strategy: trigger removal and supportive care first, then colchicine/dapsone/azathioprine and escalation for refractory disease.
DOI:10.1007/s40257-022-00736-6
openscientist CONCORDANT 90% colchicine as first-line and dapsone as second-line for chronic/relapsing LCV
OpenScientist gives the same colchicine-first / dapsone-second ladder and adds emerging biologic/JAK-inhibitor options for refractory subsets.
PMID:16249140, PMID:30268388

Allergic cutaneous vasculitis is not a Mendelian disorder; it is an acquired, multifactorial/polygenic condition with no established single causal gene.

UNANIMOUS INTEGRATED
genetic_factor
ProviderStanceScoreEvidence
falcon CONCORDANT 85% the retrieved clinical guidance treats CSVV/LCV largely as an **acquired immune-mediated** syndrome rather than a monogenic disorder.
Falcon states no causal gene is established and treats the condition as an acquired, non-monogenic syndrome.
DOI:10.1007/s40257-022-00736-6, DOI:10.1007/s11739-021-02688-x
openscientist CONCORDANT 85% No single causal gene has been identified for Allergic Cutaneous Vasculitis.
OpenScientist agrees there is no single causal gene, but goes further than Falcon by cataloguing polygenic susceptibility associations (HLA-DRB1, IL1RN, complement C2/C4, TNF) that Falcon does not report.
PMID:12473277

Narrative

Overview

Both providers characterize allergic cutaneous vasculitis as an acquired, immune-complex-mediated (Gell-Coombs type III) small-vessel vasculitis of the superficial dermal postcapillary venules, presenting with palpable purpura on the lower extremities and diagnosed by biopsy showing leukocytoclasia, fibrinoid necrosis, and RBC extravasation. Falcon (Edison Scientific Literature) delivers a concise, guideline-anchored clinical guide; the OpenScientist report is far broader (15 domains, animal models, quantified epidemiology and etiology, and a genetic-susceptibility catalogue).

Agreement

The reports converge strongly on the core mechanism (immune-complex deposition → classical complement activation with C3a/C5a → neutrophil recruitment and degranulation → fibrinoid necrosis, leukocytoclasia, and RBC extravasation), the cardinal palpable-purpura phenotype on dependent skin, biopsy of a fresh (<48 h) lesion plus DIF as the diagnostic approach, an incidence on the order of 15-38 per million per year, a favorable self-limited course, and the same treatment ladder (trigger removal and supportive care → colchicine → dapsone → corticosteroids/immunosuppressants). Both also agree the disorder is non-Mendelian.

Divergence

Divergence is mostly coverage and quantification rather than conflict. OpenScientist quantifies the etiology breakdown (drugs ~40%, infections ~20%, idiopathic up to 50%), pins the relapse rate at 18-25% (versus Falcon's ~10% chronic/relapsing framing), assigns identifiers Falcon could not retrieve (MONDO:0019552, ORPHA:889), and adds a polygenic susceptibility catalogue (HLA-DRB1, IL1RN, complement C2/C4, TNF), animal Arthus-reaction models, and emerging biologic/JAK-inhibitor therapies. Falcon uniquely foregrounds an upstream mast-cell degranulation step in the cascade and current practical dosing. No direct contradictions were found.

Integration

The harmonized mechanism, phenotype, diagnostic, epidemiologic, prognostic, treatment, and genetic-architecture findings are all suitable to integrate into kb/disorders/Allergic_Cutaneous_Vasculitis.yaml, with OpenScientist supplying the quantified etiology/epidemiology figures and Falcon supplying the guideline-anchored diagnostic and treatment mechanics.

Not integrated (leads)

Provider-specific extensions retained as research leads rather than promoted: OpenScientist's polygenic susceptibility loci, animal Arthus-reaction models, and emerging biologic/JAK-inhibitor therapies, and the urticarial-vasculitis subset detail. These require independent primary-literature verification before promotion to curated evidence.

Cross-provider synthesis comparing the falcon (concise guideline-anchored) and openscientist (comprehensive 15-domain) deep-research reports. All best_matching_text values are verbatim substrings of the cited report files; markdown emphasis markers present in the source text are retained inside quotes so they remain exact substrings. No CONTRADICTORY stances were assigned — the only differences are quantitative framing (relapse rate, etiology fractions) and breadth of coverage. Literature evidence blocks and ontology terms are intentionally omitted; they belong to the main curation pipeline on the disorder YAML.